{
    "clinical_study": {
        "@rank": "117729", 
        "arm_group": [
            {
                "arm_group_label": "Gemigliptin", 
                "arm_group_type": "Experimental", 
                "description": "50mg qd"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "After a screening, a 2-week, single-blind placebo run-in, 174 patients will be randomized in\n      a 1 : 1 ratio to the addition of either once-daily Gemigliptin 50 mg or placebo to ongoing\n      stable doses of glimepiride in combination with metformin for 24 weeks."
        }, 
        "brief_title": "Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin", 
        "condition": "T2DM", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus, Type 2"
        }, 
        "detailed_description": {
            "textblock": "Subjects will visit the center on Week 6, 12, 18 and 24 during the entire 24-week treatment\n      period. Total study duration will be approximately 26weeks and the subjects will be to\n      practice exercise/diet control together."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients with Type 2 Diabetes Mellitus\n\n          2. Adults aged \u2265 19 years old\n\n          3. Patients with HbA1c 7%~11%  at Visit 1"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "174", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01990469", 
            "org_study_id": "LG-DPCL010"
        }, 
        "intervention": {
            "arm_group_label": "Gemigliptin", 
            "intervention_name": "Gemigliptin", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Type 2 Diabetes Mellitus", 
        "lastchanged_date": "November 20, 2013", 
        "number_of_arms": "2", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change of HbAlc from baseline at Week 24", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01990469"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "LG Life Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LG Life Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}